EUVIMEDEUVIMED entdecken
Crossref

Chirality-Guided Optimization of A 2A Adenosine Receptor Antagonists for Enhanced Metabolic Stability and Antitumor Efficacy

Wen Ding, Shuhao Liu, Wenjiang Liu, Zhijing Zhang, Jingyu Zhao, Xiaolei Zhang iD, Taoda Shi iD, Wenhao Hu iD

Journal of Medicinal Chemistry · 24.07.2025 · 68 (14) · 14962-14980

DOI: 10.1021/acs.jmedchem.5c01141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.06.2025. Verfasst von Wen Ding und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, Sch…. Hauptthemen laut MEDLINE: Adenosine A2 Receptor Antagonists, Receptor, Adenosine A2A, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Special Project for Research and Development in Key areas of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blockade of the A2A adenosine receptor (A2AAR) by small-molecule antagonists holds promise for enhancing the efficacy of immune checkpoint inhibitors such as PD-L1 antibodies. However, many A2AAR antagonists suffer from limited clinical success due to poor metabolic stability. In this study, we introduce chirality into the A2AAR antagonist scaffold to address this challenge. This approach led to the discovery of (S)-E8, a chiral compound with markedly improved binding affinity, cellular activity, and in vivo potency compared with AZD4635, a Phase II clinical candidate. In contrast, its enantiomer (R)-E8 displays rapid metabolism and low efficacy, highlighting the importance of stereochemistry for therapeutic performance. Mechanistic studies identified CYP1A2 as the primary enzyme driving the metabolic differences among the enantiomers. These findings underscore the value of chirality-guided design in optimizing drug-like properties and reveal CYP1A2's pivotal role in enantioselective metabolism, offering a promising direction for the development of next-generation A2AAR antagonists.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine A2 Receptor AntagonistsReceptor, Adenosine A2AAntineoplastic AgentsHumansAnimalsStereoisomerismStructure-Activity RelationshipMiceCytochrome P-450 CYP1A2Cell Line, TumorMicrosomes, Liver

Substanzen

Adenosine A2 Receptor AntagonistsReceptor, Adenosine A2AAntineoplastic AgentsCytochrome P-450 CYP1A2

Autor:innen und Institutionen

  • State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 5100…
  • State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou 510060, China.
  • Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
  • Guangdong Basic Research Center of Excellence for Functional Molecular Engineering, Sun Yat-Sen University, Guangzhou 510006, China.
  • Division of Abdominal Tumor Multimodality Treatment and Laboratory of Cell Engineering and Immunotherapy, Cancer Center and State Key Laboratory of Biotherapy and Frontiers Science Center for Disease-related Molecular N…

ORCID-Profile: Xiaolei Zhang, Taoda Shi, Wenhao Hu

Förderung

  • Special Project for Research and Development in Key areas of Guangdong Province
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • National Natural Science Foundation of China
  • Research and Development Program of Guangzhou National Laboratory

Zitieren

APA

Ding, W., Liu, S., Liu, W., Zhang, Z., Zhao, J., Zhang, X., Shi, T., & Hu, W. (2025). Chirality-Guided Optimization of A 2A Adenosine Receptor Antagonists for Enhanced Metabolic Stability and Antitumor Efficacy. Journal of Medicinal Chemistry, 68(14), 14962-14980. https://doi.org/10.1021/acs.jmedchem.5c01141

Vancouver

Ding W, Liu S, Liu W, Zhang Z, Zhao J, Zhang X, et al. Chirality-Guided Optimization of A 2A Adenosine Receptor Antagonists for Enhanced Metabolic Stability and Antitumor Efficacy. Journal of Medicinal Chemistry. 2025;68(14):14962-14980. doi:10.1021/acs.jmedchem.5c01141

BibTeX
@article{Ding2025,
  author = {Ding, Wen and Liu, Shuhao and Liu, Wenjiang and Zhang, Zhijing and Zhao, Jingyu and Zhang, Xiaolei and Shi, Taoda and Hu, Wenhao},
  title = {Chirality-Guided Optimization of A 2A Adenosine Receptor Antagonists for Enhanced Metabolic Stability and Antitumor Efficacy},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {14},
  pages = {14962--14980},
  doi = {10.1021/acs.jmedchem.5c01141}
}
Kostenlos starten →